Humana GLP-1 coverage: PA criteria, formulary tiers, and 2026 plan rules

Humana Inc. (NYSE: HUM) — the second-largest Medicare Advantage insurer in the United States with over 7 million Medicare members as of early 2026 — covers GLP-1 receptor agonists across its commercial, Medicare Advantage, and marketplace plans, but the coverage rules differ sharply by plan type, indication, and employer benefit design. For diabetes, GLP-1 access is relatively straightforward. For weight loss, Humana has been among the more restrictive national payers.

This guide maps Humana's GLP-1 coverage policies, details prior authorization criteria by plan type and indication, explains formulary tier placement for Ozempic, Mounjaro, Wegovy, and Zepbound, and identifies common denial reasons and appeal pathways. It is independent information and not medical advice or reimbursement guidance for a specific patient or plan.

Quick answer

Key policy dates:

• Since June 2023: Humana implemented a diagnosis code requirement for all GLP-1 prescriptions, blocking weight-loss-only claims at the pharmacy level
• 2026: Humana's National Preferred Formulary places Ozempic, Mounjaro, Rybelsus, and Trulicity at Tier 3 (non-preferred drug) with PA required
• July 1, 2026: Medicare GLP-1 Bridge program begins, providing temporary coverage for Wegovy, Zepbound, and Foundayo for eligible Medicare beneficiaries with a $50 copay per 30-day supply

Who this is for

• Humana commercial, Medicare Advantage, and marketplace members and their prescribers navigating GLP-1 prior authorization
• Benefit verification specialists and hub teams handling Humana pharmacy claims
• Market access teams at GLP-1 manufacturers tracking Humana policy
• Employer benefits administrators evaluating Humana's GLP-1 weight-loss benefit options

Source standard

Every fact in this guide is sourced from Humana formulary documents, Humana.com Medicare resources, CMS publications, and published analyses dated 2025–2026. Humana coverage rules vary by plan, state, and employer. Always verify current coverage by calling the member services number on your Humana card or checking MyHumana.com.

Humana plan types and GLP-1 coverage architecture

Understanding Humana's GLP-1 coverage requires knowing which plan type the member holds, because each operates under different formulary rules:

• Humana commercial (employer-sponsored): GLP-1 coverage for both T2D and weight loss depends on whether the employer has opted into GLP-1 weight-loss benefits. Most large-group plans include T2D coverage; weight-loss coverage is employer-elected.
• Humana Medicare Advantage (MAPD): Subject to CMS rules. GLP-1s for T2D are covered under Part D. Wegovy is covered for cardiovascular risk reduction per the SELECT trial. The Medicare GLP-1 Bridge (July 2026 – December 2027) adds temporary obesity coverage.
• Humana Part D (standalone PDP): Similar to MAPD. GLP-1s for T2D covered; weight-loss coverage available only through the Bridge program starting July 2026.
• Humana Marketplace (individual/family): Coverage varies by state and plan tier. Many marketplace plans exclude GLP-1 weight-loss coverage.
• Humana Medicaid (Healthy Horizons): GLP-1 coverage depends on the state. Approximately 13 states cover GLP-1s for obesity under Medicaid; Humana Medicaid plans follow state-specific formulary rules.

GLP-1 formulary placement on Humana 2026 plans

According to Humana's 2026 commonly prescribed drug lists and formulary documents:

Humana's 2026 formulary documents note that "pharmacies must enter diagnosis code for a medically accepted indication when processing a claim for a GLP-1 receptor agonist." Claims without an appropriate diagnosis code are rejected at the point of sale.

Prior authorization criteria for diabetes GLP-1s (Ozempic, Mounjaro, Rybelsus, Trulicity)

For Humana commercial and Medicare plans, GLP-1 coverage for type 2 diabetes requires prior authorization with the following documentation:

Required documentation

1. Type 2 diabetes diagnosis with ICD-10 code (e.g., E11.9)
2. A1C ≥ 7.0% (or 6.5–6.9% with documented prior metformin trial)
3. Age ≥ 18 years
4. Prior trial of metformin or documented contraindication/intolerance
5. Prescriber attestation of medical necessity for the specific GLP-1

Clinical evidence references

• Ozempic: SUSTAIN trial program (publications in The Lancet and NEJM, 2017–2019)
• Mounjaro: SURPASS trial program; SURPASS-2 (Frias et al. 2021, NEJM) demonstrated A1C reductions of 2.0–2.3 percentage points at the highest dose
• Rybelsus: PIONEER trial program
• Trulicity: AWARD trial program

PA submission methods

• Humana provider portal (fastest option)
• Fax: Plan-specific fax number on the Humana provider website
• Phone: 1-888-204-4062 for member services; 1-877-486-2621 for Medicare employer plan PA fax
• Timeline: Standard review within 72 hours; expedited (urgent) within 24 hours

Prior authorization for weight-loss GLP-1s (Wegovy, Zepbound)

Humana commercial plans

For commercial plans that include GLP-1 weight-loss coverage, the 2026 PA criteria typically require:

1. BMI ≥ 30 (obesity), or BMI 27–29.9 with at least one weight-related comorbidity (T2D, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
2. Documentation of a structured weight management program for at least 6 months within the past 24 months
3. Prescriber attestation that lifestyle modifications alone have been inadequate
4. Age ≥ 18
5. Concurrent reduced-calorie diet and increased physical activity

For Zepbound specifically, some Humana commercial plans require step therapy — documented trial of Wegovy or an older agent — before approving Zepbound. The step requirement can be waived with documented contraindication, intolerance, or insufficient response. SURMOUNT-1 (Jastreboff et al. 2022, NEJM) showed 20.9% weight loss at 72 weeks, which Humana reviewers cite when evaluating medical necessity.

Humana Medicare Advantage / Part D

As of early 2026, Humana Medicare plans cover:

• Wegovy for cardiovascular risk reduction only — per the SELECT trial (Lincoff et al. 2023, NEJM) showing 20% reduction in major adverse cardiovascular events. PA requires established CVD with ICD-10 documentation and BMI ≥ 27.
• Zepbound for OSA only — per SURMOUNT-OSA and the December 2024 FDA approval. PA requires confirmed apnea-hypopnea index (AHI) ≥ 15 on polysomnography and BMI ≥ 30.
• No weight-loss-only coverage for Wegovy or Zepbound under standard Part D (the statutory Medicare exclusion on weight-loss drugs applies)

Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027)

The Medicare GLP-1 Bridge program, announced by CMS in March 2026, provides temporary coverage outside the standard Part D benefit. Key details:

• Eligibility: BMI ≥ 35 alone, or BMI ≥ 27 with additional clinical criteria (including comorbidities such as hypertension, heart disease, or sleep apnea). Importantly, eligible beneficiaries must meet the clinical criteria at the time of GLP-1 therapy initiation — not at the time of the Bridge PA request. If a beneficiary started therapy with a BMI of 37 and now has a BMI of 34, the prescribing provider should attest that the BMI ≥ 35 criterion was met at the time therapy was initiated.
• Covered medications: Foundayo (all formulations), Wegovy (injection and tablets, all formulations), Zepbound (KwikPen formulation only). Note: the single-dose vial and single-dose pen formulations of Zepbound are not available through the Bridge.
• Copay: $50 per 30-day supply
• Process: Prescriber submits PA request and prescription to a CMS central processor (not to Humana). The central processor reviews documentation, pays the claim, and the pharmacy coordinates dispensing. PA requests will not be accepted or processed before July 1, 2026.
• Duration: July 1, 2026 through December 31, 2027 (originally scheduled through December 2026; CMS extended the Bridge after delaying the BALANCE Model)

Common denial reasons on Humana

Appeal process

For commercial plans

1. Internal appeal: File within 60 days of denial. Submit via Humana provider portal or fax.
2. Second-level appeal: If first appeal denied, escalate within 60 days.
3. External review: Request independent medical review if internal appeals exhausted.

For Medicare plans (5-level process)

1. Redetermination: File within 60 days of denial. Submit to Humana or the Part D plan.
2. Reconsideration by IRE (Independent Review Entity): If redetermination is unfavorable.
3. ALJ hearing: Before an Administrative Law Judge.
4. Medicare Appeals Council review.
5. Federal district court review.

Documentation that moves appeals

• Letter of medical necessity from prescriber addressing the specific denial reason
• A1C trends and BMI documentation over time
• Prior medication trial records including duration, dose, and reason for discontinuation
• Comorbidity documentation with ICD-10 codes
• Clinical trial evidence cited from pivotal studies (SUSTAIN, SURPASS, SELECT, SURMOUNT-OSA)

Cost and savings pathways

Humana commercial members may be eligible for manufacturer copay assistance cards, which can reduce monthly costs. Medicare and Medicaid members cannot use manufacturer copay cards under federal anti-kickback rules.

Key takeaways

1. Humana covers all major GLP-1s for type 2 diabetes across commercial and Medicare plans, typically at Tier 3 with PA. Ensure the diagnosis code is submitted at the pharmacy.
2. Weight-loss GLP-1 coverage on Humana commercial plans depends on employer benefit design. Many Humana commercial plans exclude weight-loss GLP-1 coverage unless the employer has opted in.
3. Humana Medicare plans cover Wegovy for cardiovascular risk reduction and Zepbound for OSA, but not for weight loss alone outside the Bridge program.
4. The Medicare GLP-1 Bridge (July 2026 – December 2027) provides $50 copay coverage for eligible beneficiaries. PA goes to a CMS central processor, not to Humana.
5. The most common denial on Humana is missing diagnosis code at the pharmacy level, not a medical necessity dispute. Ensure ICD-10 codes are submitted with every GLP-1 prescription.

Sources

• Kominski A, et al. "Coverage and Prior Authorization Policies for Semaglutide, Tirzepatide, and Oral Semaglutide." PMC. Published 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12397888
• Humana. 2026 Commonly Prescribed Drug List — Humana Super National 5 MAPD. assets.humana.com. Accessed June 2026.
• Humana. 2026 Commonly Prescribed Drug List — Humana Premier PDP. assets.humana.com. Accessed June 2026.
• Humana. "Does Medicare Cover GLP-1 Weight Loss Drugs?" humana.com/medicare/medicare-resources. Published May 15, 2026.
• Humana. "Find Prior Authorization Guidelines and Forms." humana.com/pharmacy/prior-authorization-medication-approvals. Updated January 12, 2026.
• Counterforce Health. "Getting Ozempic and Mounjaro Covered by Humana in Texas." counterforcehealth.org. 2026.
• TrimRX. "Does Humana Cover GLP-1 Medications in 2026?" trimrx.com/blog. 2026.
• KFF. "What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries." kff.org. Published March 9, 2026.
• CMS. "Information for Medicare Beneficiaries — Medicare GLP-1 Bridge." cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge. Updated April 6, 2026.
• Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." NEJM. 2023;389(24):2221-2232. (SELECT trial)
• Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM. 2022;387(3):205-216. (SURMOUNT-1)
• Frias JP, et al. "Efficacy and Safety of Tirzepatide Compared with Semaglutide." NEJM. 2021;385(6):503-515. (SURPASS-2)